Damian E. Dupuy

Damian E. Dupuy holds a B.Sc. in Zoology graduating Magna Cum Laude/Phi Beta Kappa with a degree in zoology and a minor in Chemistry from the University of Massachusetts Amherst and a Doctor of Medicine from the University of Massachusetts Chan Medical School. He was an Intern at Boston University School of Medicine/Brockton Hospital. He completed his radiology residency as a chief resident in Radiology at Beth Israel Deaconess Medical Center/Harvard Medical School.{{Cite journal|last1=Healey|first1=Terrance T|last2=Ward|first2=Robert C|last3=Dupuy|first3=Damian E|date=2013-08-01|title=Ask the Experts: How important is radiofrequency ablation in lung cancer?|url=https://www.futuremedicine.com/doi/abs/10.2217/lmt.13.24|journal=Lung Cancer Management|volume=2|issue=4|pages=265–269|doi=10.2217/lmt.13.24|issn=1758-1966|url-access=subscription}}

Damian E. Dupuy's clinical interests include the current and future clinical use and optimization of image guided cancer treatment with thermal and non thermal techniques.{{Cite journal|last1=Dupuy|first1=Damian E.|last2=Shulman|first2=Maria|date=September 2010|title=Current Status of Thermal Ablation Treatments for Lung Malignancies|journal=Seminars in Interventional Radiology|language=en|volume=27|issue=3|pages=268–275|doi=10.1055/s-0030-1261785|issn=0739-9529|pmc=3324195|pmid=22550366}}{{Cite journal|last1=Dupuy|first1=Damian|last2=Shulman|first2=Maria|date=September 2010|title=Current Status of Thermal Ablation Treatments for Lung Malignancies|journal=Seminars in Interventional Radiology|language=en|volume=27|issue=3|pages=268–275|doi=10.1055/s-0030-1261785|issn=0739-9529|pmc=3324195|pmid=22550366}}{{Cite journal|last1=McTaggart|first1=Ryan A.|last2=Dupuy|first2=Damian E.|date=2007-06-01|title=Thermal Ablation of Lung Tumors|url=https://www.techvir.com/article/S1089-2516(07)00080-7/abstract|journal=Techniques in Vascular & Interventional Radiology|language=English|volume=10|issue=2|pages=102–113|doi=10.1053/j.tvir.2007.09.004|issn=1089-2516|pmid=18070688|url-access=subscription}} He researched the evaluation of Microwave Ablation Zone Variance Using Changes in Tissue Thermal and electrical Properties and also on a personalized microwave ablation treatment planning methodology based on radiomics and simulation.{{Cite journal|last1=Deshazer|first1=G.|last2=Prakash|first2=P.|last3=Hagmann|first3=M.|last4=Dupuy|first4=D.|last5=Merck|first5=D.|date=2015|title=SU-E-T-394: Evaluation of Microwave Ablation Zone Variance Based On Reported Changes in Thermal and Electrical Properties of Tissues|url=https://onlinelibrary.wiley.com/doi/abs/10.1118/1.4924755|journal=Medical Physics|language=en|volume=42|issue=6Part18|pages=3424|doi=10.1118/1.4924755|bibcode=2015MedPh..42.3424D |s2cid=120401733 |issn=2473-4209|url-access=subscription}}{{Cite journal|date=2016|title=Physical modeling of microwave ablation zone clinical margin variance|url=https://www.readcube.com/articles/10.1118%2F1.4942980|language=en|volume=43|issue=4|doi=10.1118/1.4942980|issn=2473-4209|last1=Deshazer |first1=Garron |last2=Merck |first2=Derek |last3=Hagmann |first3=Mark |last4=Dupuy |first4=Damian E. |last5=Prakash |first5=Punit |journal=Medical Physics |pages=1764–1776 |pmid=27036574 |bibcode=2016MedPh..43.1764D |url-access=subscription }}{{Cite journal|last1=McTaggart|first1=Ryan A.|last2=Dupuy|first2=Damian E.|date=2007-06-01|title=Thermal Ablation of Lung Tumors|url=https://www.techvir.com/article/S1089-2516(07)00080-7/abstract|journal=Techniques in Vascular & Interventional Radiology|language=English|volume=10|issue=2|pages=102–113|doi=10.1053/j.tvir.2007.09.004|issn=1089-2516|pmid=18070688|url-access=subscription}} He concentrated his study on local ablative procedures. Dupuy contributed to the expansion of clinical applications for the successful treatment of cancers of the kidney, liver, lung, head and neck, adrenal gland, and skeleton.{{Cite web|title=A hot – or cold – option for cancer care|url=https://www.capecodhealth.org/medical-services/cancer-care/a-hot-or-cold-option-for-cancer-care/|access-date=2021-11-15|website=www.capecodhealth.org|language=en-US}} Dupuy pioneered other cutting-edge treatments, including percutaneous microwave ablation, cryoablation, and combination therapies combining radiofrequency ablation with external radiation or brachytherapy.{{Cite journal|last1=Simon|first1=Caroline J.|last2=Dupuy|first2=Damian E.|last3=Mayo-Smith|first3=William W.|date=2005-10-01|title=Microwave Ablation: Principles and Applications|url=https://pubs.rsna.org/doi/10.1148/rg.25si055501|journal=RadioGraphics|volume=25|issue=suppl_1|pages=S69–S83|doi=10.1148/rg.25si055501|pmid=16227498 |issn=0271-5333|url-access=subscription}}{{Cite journal|last1=Callstrom|first1=Matthew R.|last2=Woodrum|first2=David A.|last3=Nichols|first3=Francis C.|last4=Palussiere|first4=Jean|last5=Buy|first5=Xavier|last6=Suh|first6=Robert D.|last7=Abtin|first7=Fereidoun G.|last8=Pua|first8=Bradley B.|last9=Madoff|first9=David C.|last10=Bagla|first10=Sandeep L.|last11=Papadouris|first11=Dimitrios C.|date=July 2020|title=Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE)|journal=Journal of Thoracic Oncology|language=en|volume=15|issue=7|pages=1200–1209|doi=10.1016/j.jtho.2020.02.022|pmid=32151777 |pmc=9201766 }} As the primary investigator of two of the first ever National Cancer Institute-funded multi-center trials studying the safety and effectiveness of radiofrequency ablation for the treatment of medically inoperable stage 1 non small cell cancer of the lung (ACOSOG/Alliance Z4033 trial){{Cite journal|last1=Dupuy|first1=Damian E.|last2=Fernando|first2=Hiran C.|last3=Hillman|first3=Shauna|last4=Ng|first4=Thomas|last5=Tan|first5=Angelina D.|last6=Sharma|first6=Amita|last7=Rilling|first7=William S.|last8=Hong|first8=Kelvin|last9=Putnam|first9=Joe B.|date=2015|title=Radiofrequency ablation of stage IA non–small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial|journal=Cancer|language=en|volume=121|issue=19|pages=3491–3498|doi=10.1002/cncr.29507|issn=1097-0142|pmc=4578219|pmid=26096694}} and radiofrequency ablation for the pain palliation of osseous metastatic disease (ACRIN 6661 trial).{{Cite journal|last1=Dupuy|first1=D. E.|last2=Liu|first2=D.|last3=Hartfeil|first3=D.|last4=Hanna|first4=L.|last5=Blume|first5=J.|last6=Ahrar|first6=K.|last7=Lopez|first7=R.|last8=Safran|first8=H.|last9=DiPetrillo|first9=T.|last10=Mayo-Smith|first10=W.|date=2007-06-20|title=Percutaneous radiofrequency ablation of painful osseous metastases: A multicenter trial: American College of Radiology Imaging Network 6661|url=https://ascopubs.org/doi/10.1200/jco.2007.25.18_suppl.9101|journal=Journal of Clinical Oncology|volume=25|issue=18_suppl|pages=9101|doi=10.1200/jco.2007.25.18_suppl.9101|issn=0732-183X|url-access=subscription}}

Damian E. Dupuy is presently a director of the tumor ablation at Cape Cod Hospital. Before obtaining his current role, he was the instructor in radiology at the Harvard Medical School from 1993 to 1997. At present, he is working as the Director of Tumor Ablation at Cape Cod Hospital. Based on his research at Brown University and Rhode Island Hospital perfecting an injectable gel-like biological nano technology device he founded a biotech company called Theromics Incorporated dedicated to the FDA approval and commercialization of a patented HeatSYNC gel technology that improves the thermal ablation zone during RFA or microwave treatments. The company has recently received a Phase 1 STTR grant from the National Science Foundation (NSF) to fund preclinical testing for FDA approval.{{Cite web|title=About Us|url=https://www.theromicsinc.com/about-us|access-date=2021-11-15|website=Theromics Inc.|language=en}}{{Cite web|title=Damian E. Dupuy Inventions, Patents and Patent Applications - Justia Patents Search|url=https://patents.justia.com/inventor/damian-e-dupuy|access-date=2021-11-15|website=patents.justia.com}}{{Cite web|title=NSF Award Search: Award # 2126555 - STTR Phase I: Thermal Diffusion Studies for a Tumor Ablation Accelerant|url=https://www.nsf.gov/awardsearch/showAward?AWD_ID=2126555&HistoricalAwards=false|access-date=2021-11-15|website=www.nsf.gov}}

Damian E. Dupuy was an elected chief resident of the New England Deaconess Hospital at Harvard Medical School. He was listed as one of America's Best Doctors continuously from 2007 to 2020. In the year 2010, he received the Publications Merit Award from the American College of Radiology Imaging Network (ACRIN). He is a fellow of American College of Radiology. In 2013 Dr. Dupuy was chosen to give the Annual Oration in Diagnostic Radiology at the Radiological Society of North America (RSNA) in Chicago, IL. In 2013 at the Annual CHEST Society meeting in Chicago, IL Dr. Dupuy received the highest Alfred Soffer Award for{{Dead link|date=April 2024 |bot=InternetArchiveBot |fix-attempted=yes }} outstanding scientific abstract for his research on the treatment of early stage lung cancer in medically inoperable patients with radiofrequency ablation (RFA).

• Image-Guided Cancer Therapy. A Multidisciplinary Approach Springer Verlag 2013.{{Cite book|url=https://doi.org/10.1007/978-1-4419-0751-6|title=Image-Guided Cancer Therapy|date=2013|publisher=Springer New York|isbn=978-1-4419-0750-9|editor-last=Dupuy|editor-first=Damian E.|location=New York, NY|language=en-gb|doi=10.1007/978-1-4419-0751-6|s2cid=44487688 |editor-last2=Fong|editor-first2=Yuman|editor-last3=McMullen|editor-first3=William N.}}
• Thermal ablation of tumours: biological mechanisms and advances in therapy.{{Cite journal|last1=Chu|first1=Katrina F.|last2=Dupuy|first2=Damian E.|date=March 2014|title=Thermal ablation of tumours: biological mechanisms and advances in therapy|url=https://www.nature.com/articles/nrc3672|journal=Nature Reviews Cancer|language=en|volume=14|issue=3|pages=199–208|doi=10.1038/nrc3672|pmid=24561446 |s2cid=9224039 |issn=1474-1768|url-access=subscription}}
• CT Densitometry and Morphology of Radiofrequency-Ablated Stage IA Non-Small Cell Lung Cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) Trial.{{Cite journal|last1=Alexander|first1=Erica S.|last2=Xiong|first2=Lillian|last3=Baird|first3=Grayson L.|last4=Fernando|first4=Hiran|last5=Dupuy|first5=Damian E.|date=February 2020|title=CT Densitometry and Morphology of Radiofrequency-Ablated Stage IA Non-Small Cell Lung Cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) Trial|journal=Journal of Vascular and Interventional Radiology|volume=31|issue=2|pages=286–293|doi=10.1016/j.jvir.2019.09.010|issn=1535-7732|pmc=6994385|pmid=31902554}}
• Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial.{{Cite journal|last1=Callstrom|first1=Matthew R.|last2=Dupuy|first2=Damian E.|last3=Solomon|first3=Stephen B.|last4=Beres|first4=Robert A.|last5=Littrup|first5=Peter J.|last6=Davis|first6=Kirkland W.|last7=Paz-Fumagalli|first7=Ricardo|last8=Hoffman|first8=Cheryl|last9=Atwell|first9=Thomas D.|last10=Charboneau|first10=J. William|last11=Schmit|first11=Grant D.|date=2013-03-01|title=Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial|journal=Cancer|volume=119|issue=5|pages=1033–1041|doi=10.1002/cncr.27793|issn=1097-0142|pmc=5757505|pmid=23065947}}
• Evaluation of a Novel Thermal Accelerant for Augmentation of Microwave Energy during Image-guided Tumor Ablation.{{Cite journal|last1=Park|first1=William Keun Chan|last2=Maxwell|first2=Aaron Wilhelm Palmer|last3=Frank|first3=Victoria Elizabeth|last4=Primmer|first4=Michael Patrick|last5=Collins|first5=Scott Andrew|last6=Baird|first6=Grayson Luderman|last7=Dupuy|first7=Damian Edward|date=2017|title=Evaluation of a Novel Thermal Accelerant for Augmentation of Microwave Energy during Image-guided Tumor Ablation|journal=Theranostics|volume=7|issue=4|pages=1026–1035|doi=10.7150/thno.18191|issn=1838-7640|pmc=5381263|pmid=28382173}}
• Lung Ablation with Irreversible Electroporation Promotes Immune Cell Infiltration by Sparing Extracellular Matrix Proteins and Vasculature: Implications for Immunotherapy.{{Cite journal|last1=Fujimori|first1=Masashi|last2=Kimura|first2=Yasushi|last3=Ueshima|first3=Eisuke|last4=Dupuy|first4=Damian E.|last5=Adusumilli|first5=Prasad S.|last6=Solomon|first6=Stephen B.|last7=Srimathveeravalli|first7=Govindarajan|date=2021-09-01|title=Lung Ablation with Irreversible Electroporation Promotes Immune Cell Infiltration by Sparing Extracellular Matrix Proteins and Vasculature: Implications for Immunotherapy|journal=Bioelectricity|volume=3|issue=3|pages=204–214|doi=10.1089/bioe.2021.0014|issn=2576-3105|pmc=8558078|pmid=34734168}}
• The in vivo performance of a novel thermal accelerant agent used for augmentation of microwave energy delivery within biologic tissues during image-guided thermal ablation: a porcine study.{{Cite journal|last1=Park|first1=William Keun Chan|last2=Maxwell|first2=Aaron Wilhelm Palmer|last3=Frank|first3=Victoria Elizabeth|last4=Primmer|first4=Michael Patrick|last5=Paul|first5=Jarod Brian|last6=Collins|first6=Scott Andrew|last7=Lombardo|first7=Kara Anne|last8=Lu|first8=Shaolei|last9=Borjeson|first9=Tiffany Marie|last10=Baird|first10=Grayson Luderman|last11=Dupuy|first11=Damian Edward|date=February 2018|title=The in vivo performance of a novel thermal accelerant agent used for augmentation of microwave energy delivery within biologic tissues during image-guided thermal ablation: a porcine study|journal=International Journal of Hyperthermia|volume=34|issue=1|pages=11–18|doi=10.1080/02656736.2017.1317367|issn=1464-5157|pmid=28540805|s2cid=43909021 |doi-access=free}}

{{reflist}}

• {{Google Scholar ID|id=gPPutioAAAAJ}}

{{Authority control}}

{{DEFAULTSORT:Dupuy, Damian E.}}

Category:University of Massachusetts Amherst alumni

Category:UMass Chan Medical School alumni

Category:Brown University faculty

Category:Living people

Category:Year of birth missing (living people)